Mounting evidence has demonstrated that circular RNAs (circRNAs) play indispensable roles in the progression of bladder cancer. Public database mining showed that hsa_circRNA_100146 (circRNA_100146) was highly expressed in bladder cancer.
Bladder cancer (BLCA) is the most common urinary tract tumor and is the 11th most malignant cancer worldwide. With the development of in-depth multisystem sequencing, an increasing number of prognostic molecular markers have been identified.
There are multiple factors contributing to a progressive decrease in the length of stay (LOS) following radical prostatectomy over the last two decades. These include the rapid transition to minimally invasive surgery, financial pressures in health care delivery, and most recently a global pandemic. While several experienced high-volume surgeons have demonstrated the safety of same-day […]
To compare two commercially available ureteral access sheaths in their ability to access the renal collecting system and assess ureteral wall trauma using a prospective, randomized trial. Ninety-five patients undergoing ureteroscopy for renal stones were randomized to Cook Flexor™ or Boston Scientific Navigator HD™ 12/14F sheaths. If the initial sheath failed to advance, an alternate […]
Michael Cookson: Thank you very much, Dr. Shore, that was an excellent presentation. It is my pleasure to introduce my co-moderator, Dr. Alicia Morgans. She’s a Medical Oncologist and Associate Professor of Medicine at Northwestern University’s Feinberg School of Medicine and we’re going to talk a little bit today about the HERO Trial. Alicia Morgans: […]
Fight Bladder Cancer charity has launched the first-ever suite of ten information booklets to support patients at every stage of their cancer journey. Over 20,000 people are diagnosed with bladder cancer every year in the UK. Following extensive research of 1,000 patients and carers,1 the charity identified that there was a major gap in the […]
Michael Cookson: Thank you. I’m Dr. Michael Cookson, Professor, and Chair at the University of Oklahoma, and I lead our GU oncology group at the Stephenson Cancer Center. It’s great to be here today, and that was a fantastic talk by Dr. Spratt, not only reviewing the historical perspectives of ADT and its use in radiation […]
Michael Cookson: It is my pleasure to introduce to you, Dr. Neal Shore. Neal is a Urologist and Medical Director at the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has been a prolific investigator and was the lead author on the HERO Phase 3 trial […]
Foundation Medicine’s pan tumor liquid biopsy test is now FDA-Approved to identify patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer who may be appropriate for treatment with LYNPARZA San Francisco, CA (UroToday.com) — Foundation Medicine, Inc. announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used […]
Michael Cookson: Hi, I’m Dr. Michael Cookson at the University of Oklahoma and a professor and chair at the Stephenson Cancer Center. It’s my pleasure to talk to you today about bone health. And that was an excellent presentation by Professor Saad. One question I had for you, and I think I saw it in […]
